Good News | Hycells Biotechnology Awarded Shanghai High-Tech Enterprise Certification
Release Date:
2024-03-06 13:57
Officially recognized · Authoritatively certified
On October 12, 2023, the Shanghai Municipal Science and Technology Commission announced the “ Notice on the Public Announcement of the Second Batch of Proposed High-Tech Enterprises for Recognition in Shanghai for 2023 , Shanghai Hycells Biotechnology Co., Ltd. is pleased to have been successfully selected. Following a three-month public announcement period, Hycells Biotechnology has officially been recognized as a Shanghai High-Tech Enterprise and has been awarded the corresponding certificate.
Public Notice on the Website of the Shanghai Municipal Science and Technology Commission
Public List of Selected Enterprises
The recognition of high-tech enterprises is guided, managed, and supervised by the Ministry of Science and Technology, the Ministry of Finance, and the State Taxation Administration, with respect to the company’s core self- Core intellectual property rights, capability in commercializing scientific and technological achievements, organizational and management level of research and development, and growth indicators Both the comprehensive assessment criteria and other requirements are set at a high standard. The state aims to encourage enterprises to intensify technological innovation, promote the commercialization of scientific and technological achievements, and facilitate industrial upgrading; this recognition is one of the most prestigious honors for technology-innovative enterprises.
The recognition as a high-tech enterprise is an assessment of Hycells Biotechnology in In areas such as technological research and development, the commercialization of innovation outcomes, and their application With official recognition and authoritative endorsement, Hycells Biotechnology will continue to benefit from preferential policies such as corporate income tax exemptions and talent settlement incentives.
Certificate of High-Tech Enterprise in Biological Sciences
Innovation Leads; Steady Accumulation Yields Great Results
Hycells Bio has invested substantial resources in platform R&D and application. As a technology-driven biotechnology company, the enterprise consistently upholds Quality First, Innovation as the Foundation Guided by its core values, the company has successfully launched a number of products and services with independent intellectual property rights in recent years, effectively empowering clients and addressing the pain points and challenges they face in the field of innovative drug discovery and development.
Hycells Biotechnology has consistently adhered to an intellectual property innovation strategy. To date, the company has filed nearly 30 IP patent applications, with more than half already granted—including two invention patents and 14 utility model patents—and the number of patent applications continues to increase year by year.
Since its establishment, Shanghai Hycells Biotechnology Co., Ltd. has built nearly 1,000 square meters of R&D laboratories, has officially obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification, and has completed the establishment of a comprehensive corporate quality management system, further enhancing the platform’s innovation capabilities.
Hycells Biotechnology places great emphasis on scientific and technological innovation, continuously increasing R&D investment, strengthening the development of its technology platforms, and constantly refining its innovation system. Moving forward, we will further consolidate our quality foundation, pursue bold innovation, and set new industry standards, with the hope of contributing our part to the field of drug discovery and development.
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board